TransCode Therapeutics Appoints Interim CFO Following Retirement of Tom Fitzgerald

TransCode Therapeutics, Inc. (NASDAQ: RNAZ), a clinical stage immuno-oncology and RNA therapeutics company, announced the retirement of Chief Financial Officer Tom Fitzgerald, effective immediately. Fitzgerald, who also served as a director, will continue to provide transition services to ensure a smooth handover. The company has appointed John Tattory as interim CFO, effective immediately.

Tattory brings over 25 years of financial and operational management experience across the pharmaceutical, medical device, and biotechnology sectors. His career includes roles at Ernst & Young LLP, Bristol-Myers Squibb, Tyco International, Cerapedics, and Windtree Therapeutics. Currently, he serves as a managing director at Stout Risius Ross, where he provides consulting CFO services primarily to privately held life science companies.

The leadership change comes at a critical time for TransCode, which is focused on developing innovative treatments for high-risk and advanced cancers. The company's lead therapeutic candidate, TTX-MC138, targets metastatic tumors that overexpress microRNA-10b, a well-documented biomarker of metastasis. TransCode also has a portfolio of other first-in-class candidates designed to mobilize the immune system to recognize and destroy cancer cells.

Fitzgerald's retirement marks the end of a tenure that began in July 2018, during which he helped guide the company through its clinical development phases. His departure could raise questions about continuity, but the appointment of Tattory, with his deep financial expertise in life sciences, aims to provide stability. Tattory's experience at large pharmaceutical firms and his current consulting role suggest he is well-equipped to manage the financial complexities of a clinical-stage biotech.

For investors, the transition highlights TransCode's commitment to maintaining strong financial leadership as it advances its pipeline. The company's focus on RNA therapeutics and immuno-oncology places it in a competitive field, where effective financial management is crucial for funding research and development. Tattory's immediate availability and background may reassure stakeholders that the company can continue its mission without disruption.

The announcement was detailed in a press release, which can be viewed at https://nnw.fm/8G3ik. TransCode's latest news and updates are available in its newsroom at https://nnw.fm/RNAZ.

As TransCode moves forward, Tattory's role will be pivotal in ensuring financial strategies align with the company's clinical goals. The biotech industry often faces volatile markets, and having a seasoned interim CFO can help navigate potential challenges. The company's ability to attract experienced talent like Tattory reflects its ongoing appeal despite leadership changes.

In summary, the CFO transition at TransCode Therapeutics underscores the importance of financial stewardship in advancing cutting-edge cancer therapies. With Tattory at the helm of financial operations, the company aims to sustain momentum in its pursuit of transformative treatments.